Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors

This publication has 16 references indexed in Scilit:

• In vitro and in vivo profile of SB 206553, a potent 5‐HT_2C/5‐HT_2B receptor antagonist with anxiolytic‐like properties
  British Journal of Pharmacology, 1996
• Cerebral tryptophan hydroxylase activity, and 5-HT1A receptor, 5-HT2A receptor, and 5-HT transporter binding in grouped and isolated Roman RHA and RLA rats: relationships with behaviours in two models of anxiety
  Psychopharmacology, 1995
• 5-HT2 receptor subtypes: A family re-united?
  Trends in Pharmacological Sciences, 1995
• 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research
  Pharmacology & Therapeutics, 1995
• Behavioural and biochemical evidence that glucocorticoids are not involved in DOI-elicited 5-HT2 receptor down-regulation
  European Journal of Pharmacology, 1993
• Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin
  Psychopharmacology, 1992
• Mianserin-induced 5-HT2 receptor downregulation results in anxiolytic effects in the elevated plus-maze test
  Drug Development Research, 1992
• Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists
  European Journal of Pharmacology, 1989
• The Influence of Ritanserin, a Serotonin Antagonist, in Anxiety Disorders: A Double-blind Placebo-controlled Study versus Lorazepam
  Pharmacopsychiatry, 1985
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
  Analytical Biochemistry, 1976